RxDoctor Payments Data

Charity Nyuguto

Family · Swansea, ILNPI 1013663160

Payments from drug & device makers

$4,057in general payments, 2019–2025

Across 203 payments — averaging $19.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$378
  • Neurocrine Biosciences, Inc.$375
  • Otsuka America Pharmaceutical, Inc.$367
  • Johnson & Johnson$236
  • Lundbeck LLC$215
  • UCB, Inc.$202
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$4,057100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,057 in reported general payments places this provider in the 90th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$91,974
Medicare patients
436
Services billed
1,269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin167$50,608
FarxigaDapagliflozin Propanediol64$28,792
EliquisApixaban51$27,001
OzempicSemaglutide22$21,947
LinzessLinaclotide33$18,477
TrulicityDulaglutide18$18,074
EntrestoSacubitril/Valsartan17$12,321
ArexvyRsvpref3 Antigen/As01e/Pf32$10,255
RexultiBrexpiprazole19$7,574
Lacosamide38$5,734
SymbicortBudesonide/Formoterol Fumarate16$4,312
DapagliflozinDapagliflozin Propanediol17$3,827
Albuterol Sulfate HfaAlbuterol Sulfate118$3,670
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$3,291
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen179$2,664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$68$50,608167 claims
AstraZenecaFarxiga, Symbicort$157$33,10480 claims
PfizerEliquis$71$27,00151 claims
Novo NordiskOzempic$108$21,94722 claims
AbbVieLinzess$33$18,47733 claims
Lilly USA, LLCTrulicity$378$18,07418 claims
NovartisEntresto$159$12,32117 claims
Otsuka America Pharmaceutical, Inc.Rexulti$367$7,57419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,941 family providers in Illinois.

Other family in Swansea

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →